Cargando…
Chimeric antigen receptor natural killer cells: a promising antitumor immunotherapy
Chimeric antigen receptor (CAR) T cells have been successfully used in adoptive cell therapy for malignancies. However, some obstacles, including side effects such as graft‐versus‐host disease and cytokine release syndrome, therapy resistance, limited sources, as well as high cost, limited the appli...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10691297/ https://www.ncbi.nlm.nih.gov/pubmed/38045827 http://dx.doi.org/10.1002/mco2.422 |
_version_ | 1785152710933217280 |
---|---|
author | Wang, Yan Jin, Shengjie Zhuang, Qiqi Liu, Na Chen, Ruyi Adam, Sofia Abdulkadir Jin, Jie Sun, Jie |
author_facet | Wang, Yan Jin, Shengjie Zhuang, Qiqi Liu, Na Chen, Ruyi Adam, Sofia Abdulkadir Jin, Jie Sun, Jie |
author_sort | Wang, Yan |
collection | PubMed |
description | Chimeric antigen receptor (CAR) T cells have been successfully used in adoptive cell therapy for malignancies. However, some obstacles, including side effects such as graft‐versus‐host disease and cytokine release syndrome, therapy resistance, limited sources, as well as high cost, limited the application of CAR T cells. Recently, CAR natural killer (NK) cells have been pursued as the effector cells for adoptive immunotherapy for their attractive merits of strong intrinsic antitumor activity and relatively mild side effects. Additionally, CAR NK cells can be available from various sources and do not require strict human leukocyte antigen matching, which suggests them as promising “off‐the‐shelf” products for clinical application. Although the use of CAR NK cells is restrained by the limited proliferation and impaired efficiency within the immunosuppressive tumor microenvironment, further investigation in optimizing CAR structure and combination therapies will overcome these challenges. This review will summarize the advancement of CAR NK cells, CAR NK cell manufacture, the clinical outcomes of CAR NK therapy, the challenges in the field, and prospective solutions. Besides, we will discuss the emerging application of other immune cells for CAR engineering. Collectively, this comprehensive review will provide a valuable and informative summary of current progress and evaluate challenges and future opportunities of CAR NK cells in tumor treatment. |
format | Online Article Text |
id | pubmed-10691297 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-106912972023-12-02 Chimeric antigen receptor natural killer cells: a promising antitumor immunotherapy Wang, Yan Jin, Shengjie Zhuang, Qiqi Liu, Na Chen, Ruyi Adam, Sofia Abdulkadir Jin, Jie Sun, Jie MedComm (2020) Reviews Chimeric antigen receptor (CAR) T cells have been successfully used in adoptive cell therapy for malignancies. However, some obstacles, including side effects such as graft‐versus‐host disease and cytokine release syndrome, therapy resistance, limited sources, as well as high cost, limited the application of CAR T cells. Recently, CAR natural killer (NK) cells have been pursued as the effector cells for adoptive immunotherapy for their attractive merits of strong intrinsic antitumor activity and relatively mild side effects. Additionally, CAR NK cells can be available from various sources and do not require strict human leukocyte antigen matching, which suggests them as promising “off‐the‐shelf” products for clinical application. Although the use of CAR NK cells is restrained by the limited proliferation and impaired efficiency within the immunosuppressive tumor microenvironment, further investigation in optimizing CAR structure and combination therapies will overcome these challenges. This review will summarize the advancement of CAR NK cells, CAR NK cell manufacture, the clinical outcomes of CAR NK therapy, the challenges in the field, and prospective solutions. Besides, we will discuss the emerging application of other immune cells for CAR engineering. Collectively, this comprehensive review will provide a valuable and informative summary of current progress and evaluate challenges and future opportunities of CAR NK cells in tumor treatment. John Wiley and Sons Inc. 2023-12-01 /pmc/articles/PMC10691297/ /pubmed/38045827 http://dx.doi.org/10.1002/mco2.422 Text en © 2023 The Authors. MedComm published by Sichuan International Medical Exchange & Promotion Association (SCIMEA) and John Wiley & Sons Australia, Ltd. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Reviews Wang, Yan Jin, Shengjie Zhuang, Qiqi Liu, Na Chen, Ruyi Adam, Sofia Abdulkadir Jin, Jie Sun, Jie Chimeric antigen receptor natural killer cells: a promising antitumor immunotherapy |
title | Chimeric antigen receptor natural killer cells: a promising antitumor immunotherapy |
title_full | Chimeric antigen receptor natural killer cells: a promising antitumor immunotherapy |
title_fullStr | Chimeric antigen receptor natural killer cells: a promising antitumor immunotherapy |
title_full_unstemmed | Chimeric antigen receptor natural killer cells: a promising antitumor immunotherapy |
title_short | Chimeric antigen receptor natural killer cells: a promising antitumor immunotherapy |
title_sort | chimeric antigen receptor natural killer cells: a promising antitumor immunotherapy |
topic | Reviews |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10691297/ https://www.ncbi.nlm.nih.gov/pubmed/38045827 http://dx.doi.org/10.1002/mco2.422 |
work_keys_str_mv | AT wangyan chimericantigenreceptornaturalkillercellsapromisingantitumorimmunotherapy AT jinshengjie chimericantigenreceptornaturalkillercellsapromisingantitumorimmunotherapy AT zhuangqiqi chimericantigenreceptornaturalkillercellsapromisingantitumorimmunotherapy AT liuna chimericantigenreceptornaturalkillercellsapromisingantitumorimmunotherapy AT chenruyi chimericantigenreceptornaturalkillercellsapromisingantitumorimmunotherapy AT adamsofiaabdulkadir chimericantigenreceptornaturalkillercellsapromisingantitumorimmunotherapy AT jinjie chimericantigenreceptornaturalkillercellsapromisingantitumorimmunotherapy AT sunjie chimericantigenreceptornaturalkillercellsapromisingantitumorimmunotherapy |